KEY POINTS
- Eli Lilly guided full-year 2026 revenue to $80 billion to $83 billion, a 25% jump at the midpoint, after the April 1 FDA approval of orforglipron — branded as Foundayo — opened the oral GLP-1 market.
- Phase 3 ATTAIN-1 trial data showed up to 27.3 pounds average weight loss at 72 weeks across all three doses, with a safety profile consistent with injectable GLP-1 therapies.
- Lilly now holds an estimated 60.5% of the total incretin market, leaving Novo Nordisk in defense mode — the next catalyst is the launch curve through Q3 and any payer formulary decisions.
Eli Lilly guided its full-year 2026 revenue to a range of $80 billion to $83 billion, a 25% jump at the midpoint over 2025 and well above the Street's prior models, after the FDA approved orforglipron — the first daily oral GLP-1 pill, branded Foundayo — for chronic weight management on April 1. The approval reset the structure of the obesity drug market and pushed Lilly's estimated share of the total incretin business to roughly 60.5%, leaving Novo Nordisk on the defensive after a decade of category leadership.
The Q1 2026 earnings call lands in early May, but the data the market is already trading on came out of two simultaneous releases Wednesday. The first is the Phase 3 ATTAIN-1 trial paper in The New England Journal of Medicine, showing all three orforglipron doses (6 mg, 12 mg, and 36 mg) hit the primary endpoint of superior body weight reduction versus placebo with up to 27.3 pounds of average loss at 72 weeks. The second is the Lancet paper on the head-to-head trial against oral semaglutide in Type 2 diabetes, in which orforglipron delivered superior blood sugar control and superior weight loss across endpoints.
Why the Pill Changes the Market Math
The GLP-1 category has been an injection-only business since the original Ozempic and Wegovy approvals. That structure put a hard ceiling on the total addressable market — somewhere around 120 million eligible U.S. patients with obesity or Type 2 diabetes, of whom roughly 8 million were on injectable therapy by the end of 2025. The injection requirement is the single largest persistence constraint in the category. Patients drop off in the first 12 weeks at rates of 30% to 50% depending on the cohort.
A daily pill changes the persistence math materially. Industry surveys have consistently shown that an oral GLP-1 with comparable efficacy would expand the addressable market by 40% to 60% over the medium term, with the largest gains coming in patients who never started an injectable in the first place. Foundayo's profile — 27.3 pounds average loss, no food or water restrictions on dosing, safety consistent with injectables — sits on the high end of what investors had penciled in before the trial readouts.
The pricing strategy is the next uncertain. Lilly has not yet guided publicly on Foundayo wholesale acquisition cost, but commentary from the company suggests the launch list price will sit at a meaningful discount to the injectable Mounjaro and Zepbound franchises. That choice serves two ends. It captures price-sensitive patients who would otherwise stay on lifestyle interventions, and it makes the formulary case to payers for broader coverage at the moment when major insurers are recalibrating their obesity drug reimbursement frameworks.
Novo Nordisk Faces a Step-Function Problem
The asymmetry between Lilly's position and Novo Nordisk's is now wider than it has ever been. Novo's GLP-1 portfolio remains injection-only in obesity, with an oral semaglutide approval limited to Type 2 diabetes. The Lancet head-to-head data — orforglipron beating oral semaglutide on both glycemic control and weight loss — closes the option of a clean defensive pivot. Novo will need to bring its own next-generation oral candidate, CagriSema or another internal program, into Phase 3 readouts before it can re-enter the conversation with comparable evidence. That timeline runs into 2027 and likely beyond.
The market is already pricing the asymmetry. Lilly shares are up roughly 18% year-to-date through April 29 against the S&P 500's roughly 10% gain. Novo Nordisk's ADRs are down 14% over the same period. The pair trade — long Lilly, short Novo — has been the cleanest single expression of the GLP-1 category structure shift in 2026.
What to Watch Next
The first read on Foundayo's commercial launch will come in the Q2 print in early August, when the company will provide initial prescription volume data. Industry forecasts cluster around 200,000 to 350,000 weekly prescriptions by quarter-end, a launch curve that would compare favorably with Wegovy's first three months. Below 150,000 weekly scripts by mid-July would be a disappointment that opens questions about either pricing, payer coverage, or supply.
Beyond the launch curve, three other catalysts matter. First, the European Medicines Agency review of orforglipron, with a CHMP opinion expected in the third quarter. Second, the readout of the cardiovascular outcomes trial that Lilly is running in parallel — positive cardiovascular data would unlock the much larger primary prevention market. Third, the FDA's eventual ruling on whether to require step therapy or other utilization management for the oral pill at the public payer level, a decision that will shape the Medicare and Medicaid revenue contribution from 2027 onward. The combination of those three reads, layered on top of the launch trajectory itself, will determine whether the $80 billion to $83 billion 2026 guide is the new floor or the new ceiling.
